<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35642505</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2379-5042</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>29</Day></PubDate></JournalIssue><Title>mSphere</Title><ISOAbbreviation>mSphere</ISOAbbreviation></Journal><ArticleTitle>Development of an Enzyme-Linked Immunosorbent Assay for Detection of the Native Conformation of Enterovirus A71.</ArticleTitle><Pagination><StartPage>e0008822</StartPage><MedlinePgn>e0008822</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00088-22</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/msphere.00088-22</ELocationID><Abstract><AbstractText>Enterovirus A71 (EVA71) is a medically important virus that is commonly associated with hand, foot, and mouth disease (HFMD). It is responsible for periodic outbreaks, resulting in significant economic impact and loss of life. Vaccination offers the potential to control future outbreaks, and vaccine development has been increasingly the focus of global research efforts. However, antigenic characterization of vaccine candidates is challenging because there are few tools to characterize the different antigenic forms of the virus. As with other picornaviruses, EVA71 virions exist in two antigenic states, native (NAg) and expanded (HAg). It is likely that the composition of vaccines, in terms of the proportions of NAg and HAg, will be important for vaccine efficacy and batch-to-batch consistency. This paper describes the development of a single-chain fused variable (scFv) domain fragment and the optimization of a sandwich enzyme-linked immunosorbent assay (ELISA) for the specific detection of the NAg conformation of EVA71. NAg specificity of the scFv was demonstrated using purified EVA71, and conversion of NAg to HAg by heating resulted in a loss of binding. We have thus developed an effective tool for characterization of the specific antigenic state of EVA71. <b>IMPORTANCE</b> EVA71 is a medically important virus that is commonly associated with HFMD, resulting in periodic outbreaks, significant economic impact, and loss of life. Vaccination offers the potential to curtail future outbreaks, and vaccine development has been increasingly the focus of global research efforts. However, antigenic characterization of vaccine candidates is challenging because there are very limited effective tools to characterize the different antigenic forms of EV71. As with other picornaviruses, EVA71 virions exist in two antigenic states, native and expanded. This paper describes the development of an scFv and the optimization of a sandwich ELISA for the specific detection of the native conformation of EVA71 as an effective tool for characterization of the specific antigenic state of EVA71.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kingston</LastName><ForeName>Natalie J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leedsgrid.9909.9, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grehan</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leedsgrid.9909.9, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snowden</LastName><ForeName>Joseph S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0001-7857-0634</Identifier><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leedsgrid.9909.9, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shegdar</LastName><ForeName>Mona</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leedsgrid.9909.9, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macadam</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowlands</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-4742-9272</Identifier><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leedsgrid.9909.9, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stonehouse</LastName><ForeName>Nicola J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0003-1146-5519</Identifier><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leedsgrid.9909.9, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>108466/Z/15/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/P022626/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AI169457</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>102174/B/13/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>204825/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>mSphere</MedlineTA><NlmUniqueID>101674533</NlmUniqueID><ISSNLinking>2379-5042</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EVA71</Keyword><Keyword MajorTopicYN="N">enterovirus A71</Keyword><Keyword MajorTopicYN="N">sandwich ELISA</Keyword><Keyword MajorTopicYN="N">scFv</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>4</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35642505</ArticleId><ArticleId IdType="pmc">PMC9241546</ArticleId><ArticleId IdType="doi">10.1128/msphere.00088-22</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lei D, Griffiths E, Martin J. 2020. WHO working group meeting to develop WHO recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines. Vaccine 38:4917&#x2013;4923. doi:10.1016/j.vaccine.2020.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.05.001</ArticleId><ArticleId IdType="pmc">PMC7327506</ArticleId><ArticleId IdType="pubmed">32418797</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, Hu Y, Ji T, Song L, Liang Q, Zhang B, Gao Q, Li J, Wang S, Hu Y, Gu S, Zhang J, Yao G, Gu J, Wang X, Zhou Y, Chen C, Zhang M, Cao M, Wang J, Wang H, Wang N. 2014. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 370:818&#x2013;828. doi:10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Li YP, Deng HL, Wang MQ, Wang WJ, Wang J, Wu FP, Dang SS. 2020. Association of gene polymorphisms of CD55 with susceptibility to and severity of hand, foot, and mouth disease caused by enterovirus 71 in the Han Chinese population. J Med Virol 92:3119&#x2013;3124. doi:10.1002/jmv.26088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26088</ArticleId><ArticleId IdType="pubmed">32470169</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Wang MQ, Liu CR, Deng HL, Wu Y, Dang SS, Xu LH. 2021. Polymorphisms in the DC-SIGN gene and their association with the severity of hand, foot, and mouth disease caused by enterovirus 71. Arch Virol 166:1133&#x2013;1140. doi:10.1007/s00705-021-04991-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-021-04991-6</ArticleId><ArticleId IdType="pubmed">33590343</ArticleId></ArticleIdList></Reference><Reference><Citation>Yen TY, Shih WL, Huang YC, Lee JT, Huang LM, Chang LY. 2018. Polymorphisms in enterovirus 71 receptors associated with susceptibility and clinical severity. PLoS One 13:e0206769. doi:10.1371/journal.pone.0206769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0206769</ArticleId><ArticleId IdType="pmc">PMC6218064</ArticleId><ArticleId IdType="pubmed">30395634</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia MY, Chung WY, Chiang PS, Chien YS, Ho MS, Lee MS. 2014. Monitoring antigenic variations of enterovirus 71: implications for virus surveillance and vaccine development. PLoS Negl Trop Dis 8:e3044. doi:10.1371/journal.pntd.0003044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0003044</ArticleId><ArticleId IdType="pmc">PMC4109910</ArticleId><ArticleId IdType="pubmed">25058733</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T, Kolpe AB, Kiener TK, Chow VT, Kwang J. 2011. Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice. PLoS One 6:e21757. doi:10.1371/journal.pone.0021757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021757</ArticleId><ArticleId IdType="pmc">PMC3128602</ArticleId><ArticleId IdType="pubmed">21747954</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu P, Wang Y, Tao L, Wu X, Wu W. 2019. Recombinant Lactococcus lactis secreting viral protein 1 of enterovirus 71 and its immunogenicity in mice. Biotechnol Lett 41:867&#x2013;872. doi:10.1007/s10529-019-02695-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10529-019-02695-1</ArticleId><ArticleId IdType="pubmed">31119429</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL. 2007. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9:1299&#x2013;1306. doi:10.1016/j.micinf.2007.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. 2007. Identification of neutralizing linear epitopes from the VP1 capsid protein of enterovirus 71 using synthetic peptides. Virus Res 125:61&#x2013;68. doi:10.1016/j.virusres.2006.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JN, Wang W, Duo JY, Hao Y, Ma CM, Li WB, Lin SZ, Gao XZ, Liu XL, Xu YF, Xu WB, Qin C, Zhang LF. 2010. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 28:7444&#x2013;7451. doi:10.1016/j.vaccine.2010.08.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.080</ArticleId><ArticleId IdType="pubmed">20831911</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, Guo MS, Chow YH, Yang WS, Chang KH, Sia C, Chong P. 2011. Identification and characterization of a cross-neutralization epitope of enterovirus 71. Vaccine 29:4362&#x2013;4372. doi:10.1016/j.vaccine.2011.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC. 2008. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26:1855&#x2013;1862. doi:10.1016/j.vaccine.2008.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Ku Z, Liu Q, Wang X, Chen T, Ye X, Li D, Jin X, Huang Z. 2015. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine 33:2335&#x2013;2341. doi:10.1016/j.vaccine.2015.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.03.034</ArticleId><ArticleId IdType="pubmed">25820068</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HY, Han JF, Qin CF, Chen R. 2013. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 31:3281&#x2013;3287. doi:10.1016/j.vaccine.2013.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.019</ArticleId><ArticleId IdType="pubmed">23726823</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, Mizuta K, Iwasaki T, Sata T, Wakita T, Shimizu H. 2007. An attenuated strain of enterovirus 71 belonging to genotype A showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 81:9386&#x2013;9395. doi:10.1128/JVI.02856-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02856-06</ArticleId><ArticleId IdType="pmc">PMC1951441</ArticleId><ArticleId IdType="pubmed">17567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, Walter TS, Evans G, Axford D, Owen R, Rowlands DJ, Wang J, Stuart DI, Fry EE, Rao Z. 2012. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 19:424&#x2013;429. doi:10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Cifuente JO, Lee H, Yoder JD, Shingler KL, Carnegie MS, Yoder JL, Ashley RE, Makhov AM, Conway JF, Hafenstein S. 2013. Structures of the procapsid and mature virion of enterovirus 71 strain 1095. J Virol 87:7637&#x2013;7645. doi:10.1128/JVI.03519-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03519-12</ArticleId><ArticleId IdType="pmc">PMC3700288</ArticleId><ArticleId IdType="pubmed">23637404</ArticleId></ArticleIdList></Reference><Reference><Citation>Shingler KL, Yoder JL, Carnegie MS, Ashley RE, Makhov AM, Conway JF, Hafenstein S. 2013. The enterovirus 71 A-particle forms a gateway to allow genome release: a cryoEM study of picornavirus uncoating. PLoS Pathog 9:e1003240. doi:10.1371/journal.ppat.1003240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003240</ArticleId><ArticleId IdType="pmc">PMC3605244</ArticleId><ArticleId IdType="pubmed">23555253</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu K, Ding J, Han JF, Zhang Y, Wu XY, He YL, Qin CF, Chen R. 2014. Human enterovirus 71 uncoating captured at atomic resolution. J Virol 88:3114&#x2013;3126. doi:10.1128/JVI.03029-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03029-13</ArticleId><ArticleId IdType="pmc">PMC3957924</ArticleId><ArticleId IdType="pubmed">24352461</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, Chen CY, Lin SY, Chung YC, Chiu HY, Chi WK, Lin YL, Chiang BL, Chen WJ, Hu YC. 2010. Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Vaccine 28:6951&#x2013;6957. doi:10.1016/j.vaccine.2010.08.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.052</ArticleId><ArticleId IdType="pubmed">20797455</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, Mao Q, Gao Q, Li X, Dong C, Yu X, Yao X, Li F, Yin W, Li Q, Shen X, Wang J. 2011. Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 29:9668&#x2013;9674. doi:10.1016/j.vaccine.2011.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.10.018</ArticleId><ArticleId IdType="pubmed">22015395</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim PY, Cardosa MJ. 2019. Development of a sandwich ELISA to detect virus-like-particles in enterovirus A71 vaccines. J Virol Methods 270:113&#x2013;119. doi:10.1016/j.jviromet.2019.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2019.05.005</ArticleId><ArticleId IdType="pubmed">31100287</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chang HW, Yang G, Chiang JR, Chow YH, Sai IH, Chang JY, Lin SC, Sia C, Hsiao CH, Chou AH, Chong P. 2011. Development of a quantitative enzyme linked immunosorbent assay for monitoring the enterovirus 71 vaccine manufacturing process. J Virol Methods 176:60&#x2013;68. doi:10.1016/j.jviromet.2011.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2011.06.001</ArticleId><ArticleId IdType="pubmed">21704080</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KA, Chen MF, Huang YC, Shih SR, Chiu CH, Lin JJ, Wang JR, Tsao KC, Lin TY. 2017. Epitope-associated and specificity-focused features of EV71-neutralizing antibody repertoires from plasmablasts of infected children. Nat Commun 8:762. doi:10.1038/s41467-017-00736-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00736-9</ArticleId><ArticleId IdType="pmc">PMC5624920</ArticleId><ArticleId IdType="pubmed">28970483</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KA, Zhou D, Fry EE, Kotecha A, Huang PN, Yang SL, Tsao KC, Huang YC, Lin TY, Ren J, Stuart DI. 2020. Structural and functional analysis of protective antibodies targeting the threefold plateau of enterovirus 71. Nat Commun 11:5253. doi:10.1038/s41467-020-19013-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19013-3</ArticleId><ArticleId IdType="pmc">PMC7567869</ArticleId><ArticleId IdType="pubmed">33067459</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing J, Wang Y, Sun Y, Huang J, Yan W, Wang J, Su D, Ni C, Li J, Rao Z, Liu L, Lou Z. 2014. Cyclophilin A associates with enterovirus-71 virus capsid and plays an essential role in viral infection as an uncoating regulator. PLoS Pathog 10:e1004422. doi:10.1371/journal.ppat.1004422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004422</ArticleId><ArticleId IdType="pmc">PMC4183573</ArticleId><ArticleId IdType="pubmed">25275585</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KA, Huang PN, Huang YC, Yang SL, Tsao KC, Chiu CH, Shih SR, Lin TY. 2020. Emergence of genotype C1 enterovirus A71 and its link with antigenic variation of virus in Taiwan. PLoS Pathog 16:e1008857. doi:10.1371/journal.ppat.1008857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1008857</ArticleId><ArticleId IdType="pmc">PMC7521691</ArticleId><ArticleId IdType="pubmed">32936838</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D, Zhao Y, Kotecha A, Fry EE, Kelly JT, Wang X, Rao Z, Rowlands DJ, Ren J, Stuart DI. 2019. Unexpected mode of engagement between enterovirus 71 and its receptor SCARB2. Nat Microbiol 4:414&#x2013;419. doi:10.1038/s41564-018-0319-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0319-z</ArticleId><ArticleId IdType="pubmed">30531980</ArticleId></ArticleIdList></Reference><Reference><Citation>Andris-Widhopf J, Rader C, Steinberger P, Fuller R, Barbas CF, III.. 2000. Methods for the generation of chicken monoclonal antibody fragments by phage display. J Immunol Methods 242:159&#x2013;181. doi:10.1016/S0022-1759(00)00221-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-1759(00)00221-0</ArticleId><ArticleId IdType="pubmed">10986398</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherry L, Grehan K, Snowden JS, Knight ML, Adeyemi OO, Rowlands DJ, Stonehouse NJ. 2020. Comparative molecular biology approaches for the production of poliovirus virus-like particles using Pichia pastoris. mSphere 5:e00838-19. doi:10.1128/mSphere.00838-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.00838-19</ArticleId><ArticleId IdType="pmc">PMC7067596</ArticleId><ArticleId IdType="pubmed">32161150</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am J Hyg 27:493&#x2013;497. doi:10.1093/oxfordjournals.aje.a118408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a118408</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>